Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Eva Hoster, Andrea Kerkhoff et al.|The Lancet|2024Cited by 135
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim Linton, Julie M. Vose, Umberto Vitolo et al.|The Lancet Haematology|2024Cited by 134
Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cellsSirpa Leppä|International Journal of Oncology|2009Cited by 62
Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion CohortKim Linton, Catherine Thiéblemont, Wojciech Jurczak et al.|Blood|2023Cited by 38
137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIALMouhamad Khouja, Christiane Pott, Vindi Jurinović et al.|Hematological Oncology|2025Cited by 1